The partnership will bring premium EU-grown cannabis to Australian patients, while positioning Lyphe Australia to access a diverse range of cannabis genetics
Portuguese-based medical cannabis cultivator, Gro-Vida, has partnered with Lyphe Australia for an exclusive supply agreement to bring EU-grown medical cannabis into the Australian market. The two businesses working in collaboration represent a major step forward in Lyphe Australia’s goal in providing high quality products as well as maintaining a dependable supply chain for patients. For Gro-Vida, this partnership opens new avenues to expand its reach in the Australian market, leveraging Lyphe’s established distribution network, to meet growing demand in Australia.
“We are thrilled to see the expansion of Gro-Vida grown products in the Australian medical market. Patients require low-cost, high-quality options and I believe this collaboration will satisfy that need.” notes Mallory Bodnar, Managing Director of Gro-Vida.
This partnership will allow Lyphe Australia to elevate the quality, consistency and diversity of their medical cannabis offering. “We recognize that patient needs will continually evolve, and as a patient-centric company, we must be poised to evolve with the demand” comments Kevin Nafte, General Manager for Lyphe Australia. By leveraging Gro-Vida’s diverse genetic repository Lyphe Australia is now positioned to bring a wide-range of cultivars to the Australian market.
Initial launch cultivars include: Super Lemon Haze, MK Ultra and Wappa, and are available immediately to Australian medical cannabis patients who can already have these products be prescribed by approved practitioners.
Gro-Vida is a leader in the cultivation, production, and manufacturing of phytocannabinoid therapeutics, supplying pharmaceutical partners throughout the United Kingdom, European Union, and Australia. Gro-Vida provides GACP and EU-GMP-certified products to the global market, ensuring the highest standards of quality, safety, and efficacy to its partners.
